453 related articles for article (PubMed ID: 25694537)
1. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry.
Beyer-Westendorf J; Förster K; Ebertz F; Gelbricht V; Schreier T; Göbelt M; Michalski F; Endig H; Sahin K; Tittl L; Weiss N
Europace; 2015 Apr; 17(4):530-8. PubMed ID: 25694537
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
Hecker J; Marten S; Keller L; Helmert S; Michalski F; Werth S; Sahin K; Tittl L; Beyer-Westendorf J
Thromb Haemost; 2016 May; 115(5):939-49. PubMed ID: 26791999
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
Beyer-Westendorf J; Ebertz F; Förster K; Gelbricht V; Michalski F; Köhler C; Werth S; Endig H; Pannach S; Tittl L; Sahin K; Daschkow K; Weiss N
Thromb Haemost; 2015 Jun; 113(6):1247-57. PubMed ID: 25739533
[TBL] [Abstract][Full Text] [Related]
4. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation.
Beyer-Westendorf J; Ehlken B; Evers T
Europace; 2016 Aug; 18(8):1150-7. PubMed ID: 26830891
[TBL] [Abstract][Full Text] [Related]
5. Patterns of atrial fibrillation anticoagulation with rivaroxaban - 7-year follow-up from the Dresden NOAC registry.
Tittl L; Marten S; Naue C; Beyer-Westendorf J
Thromb Res; 2024 Apr; 236():61-67. PubMed ID: 38394987
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
7. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
[TBL] [Abstract][Full Text] [Related]
8. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.
Martinez C; Katholing A; Wallenhorst C; Freedman SB
Thromb Haemost; 2016 Jan; 115(1):31-9. PubMed ID: 26246112
[TBL] [Abstract][Full Text] [Related]
9. Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation.
Jackevicius CA; Tsadok MA; Essebag V; Atzema C; Eisenberg MJ; Tu JV; Lu L; Rahme E; Ho PM; Turakhia M; Humphries KH; Behlouli H; Zhou L; Pilote L
Heart; 2017 Sep; 103(17):1331-1338. PubMed ID: 28286333
[TBL] [Abstract][Full Text] [Related]
10. 5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry.
Tittl L; Marten S; Naue C; Beyer-Westendorf J
Thromb Res; 2021 Jun; 202():24-30. PubMed ID: 33711755
[TBL] [Abstract][Full Text] [Related]
11. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
[TBL] [Abstract][Full Text] [Related]
13. Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: the Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study.
Engelberger RP; Noll G; Schmidt D; Alatri A; Frei B; Kaiser WE; Kucher N
Eur J Intern Med; 2015 Sep; 26(7):508-14. PubMed ID: 25935131
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry.
Helmert S; Marten S; Mizera H; Reitter A; Sahin K; Tittl L; Beyer-Westendorf J
J Thromb Thrombolysis; 2017 Aug; 44(2):169-178. PubMed ID: 28643004
[TBL] [Abstract][Full Text] [Related]
15. Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
Hellfritzsch M; Husted SE; Grove EL; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A
Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):187-194. PubMed ID: 27580086
[TBL] [Abstract][Full Text] [Related]
16. Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry.
Königsbrügge O; Simon A; Domanovits H; Pabinger I; Ay C
BMC Cardiovasc Disord; 2016 Dec; 16(1):254. PubMed ID: 27938343
[TBL] [Abstract][Full Text] [Related]
17. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry.
Beyer-Westendorf J; Gelbricht V; Förster K; Ebertz F; Köhler C; Werth S; Kuhlisch E; Stange T; Thieme C; Daschkow K; Weiss N
Eur Heart J; 2014 Jul; 35(28):1888-96. PubMed ID: 24394381
[TBL] [Abstract][Full Text] [Related]
18. Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation - Data from the Ljubljana Registry.
Vene N; Mavri A; Gubenšek M; Tratar G; Vižintin Cuderman T; Pohar Perme M; Blinc A
PLoS One; 2016; 11(6):e0156943. PubMed ID: 27280704
[TBL] [Abstract][Full Text] [Related]
19. Venous thromboembolism therapy with rivaroxaban in daily-care patients: Results from the Dresden NOAC registry.
Keller L; Marten S; Hecker J; Sahin K; Tittl L; Beyer-Westendorf J
Int J Cardiol; 2018 Apr; 257():276-282. PubMed ID: 29506708
[TBL] [Abstract][Full Text] [Related]
20. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.
Cappato R; Marchlinski FE; Hohnloser SH; Naccarelli GV; Xiang J; Wilber DJ; Ma CS; Hess S; Wells DS; Juang G; Vijgen J; Hügl BJ; Balasubramaniam R; De Chillou C; Davies DW; Fields LE; Natale A;
Eur Heart J; 2015 Jul; 36(28):1805-11. PubMed ID: 25975659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]